Citation Information :
Mavila VK, Kuppadakath NM, Chandroth MC, Mambally A. Multisystem Inflammatory Syndrome in Children with COVID-19: Clinical Profile and Comparison in Two Age Groups. Pediatr Inf Dis 2023; 5 (1):10-16.
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may result in multisystem inflammatory syndrome in children (MIS-C). It manifests later in the course of SARS-CoV-2 infection and presents with higher severity. Aim: To describe the clinical spectrum of illness and to compare the clinical profile, management and outcome in two age groups; upto 5 years and >5 years. Materials and methods: Observational study. Children satisfying World Health Organization (WHO) MIS-C criteria admitted in the hospital during the study period were included in the study. Results: A total of 44 children were included in the study. The median age was 6.5 years, interquartile range (IQR) was 3.92 to 10 years. Gastrointestinal symptoms were the commonest presentation, 70.45%. Gastrointestinal symptoms and shock were seen in children of >5 years and the difference was statistically significant. Hyperferritinemia and lymphopenia were statistically significant in the older age group. Intravenous immunoglobulin (IVIG) was used in 88.24% of children up to 5 years of age group. Around 55.56% of children of >5 years were managed with steroids alone. Conclusion: The course and short-term outcome of MIS-C are generally favorable.
CDC COVID-19 Response Team. Coronavirus disease 2019 in children- United States, February 12-April 2, 2020 (Internet). MMWR. Morbidity and mortality weekly report. Centers for Disease Control and Prevention; 2020 (cited 2021 Nov 18). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147903/
Covid-19 paediatric multisystem-RCPCH(Internet). (cited 2021 Nov 18). Available from: https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-inflammatory syndrome-20200501.pdf
Information for healthcare providers about multisystem inflammatory syndrome in children (mis-c)(Internet). Centres for Disease Control and Prevention. Centers for Disease Control and Prevention; 2021(cited2021Nov20). Available from: https://www.cdc.gov/mis/mis-c/hcp/index.html
Multisystem inflammatory syndrome in children and adolescents (Internet).(cited 2021 Nov 20). Available from: https://apps.who.int/iris/bitstream/handle/10665/332095/WHO-2019-nCoV-Sci_Brief-Multisystem_Syndrome_Children-2020.1-eng.pdf
Nakra NA, Blumberg DA, Herrera-Guerra A, et al. Multisystem inflammatory syndrome in children (mis-C) following SARS-COV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children (Basel) 2020;7(7):69. DOI: 10.3390/children7070069
Kerala State IT Mission C-DIT. Gok Dashboard: Official kerala COVID-19 statistics (Internet). Official Kerala Dashboard. (cited 2021 Nov 20). Available from: https://dashboard.kerala.gov.in/covid/
Guidelines-Post-COVID-. Guidelines-Post-COVID-Clinics.pdf (Internet). (cited 2021 Nov 26). Accessed November 26, 2021. Available from: https://dhs.kerala.gov.in/wp-content/uploads/2020/10/
BDSS Corp. Released 2020.co Guide Statistics software, Version 1.0, India: BDSS Corp.
Penner J, Abdel-Rahman O, Grant K, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK Tertiary Paediatric Hospital: a retrospective cohort study. Lancet Child Adolesc Health 2021;5(7):473–482. DOI: 10.1016/S2352-4642(21)00138-3
Rauf A, Vijayan A, John ST, et al. Multisystem inflammatory syndrome with features of atypical Kawasaki disease during COVID-19 pandemic. Indian J Pediatr 2020;87(9):745–747. DOI: 10.1007/s12098-020-03357-1
Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis 2020;20(11):e276–e288. DOI: 10.1016/S1473-3099(20)30651-4
Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol 2012;22(2):79–85. DOI: 10.2188/jea.je20110131
Miller J, Cantor A, Zachariah P, et al. Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children that is related to coronavirus disease 2019: a single centre experience of 44 cases. Gastroenterology 2020;159(4):1571–1574.e2. DOI: 10.1053/j.gastro.2020.05.079
Garcia-Salido A, de Carlos Vicente JC, Belda Hofheinz S, et al. Severe manifestations of SARS-COV-2 in children and adolescents: from covid-19 pneumonia to multisystem inflammatory syndrome: a multicenter study in pediatric intensive care units in Spain. Critical Care 2020;24(1):1–13. DOI: 10.1186/s13054-020-03332-4
Jain S, Sen S, Lakshmi Venkateshiah S, et al. Multisystem inflammatory syndrome in children with COVID-19 in Mumbai, India. Indian Pediatr 2020;57(11):1015–1019. DOI: 10.1007/s13312-020-2026-0
Sugunan S, Bindusha S, Geetha S, et al. Clinical profile and short-term outcome of children with SARS-COV-2 related multisystem inflammatory syndrome (mis-c) treated with pulse methylprednisolone. Indian Pediatr 2021;58(8):718–722. DOI: 10.1007/s13312-021-2277-4
Zhao Y, Yin L, Patel J, et al. The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with Covid-19: a meta-analysis. J Med Virol 2021;93(7): 4358–4369. DOI: 10.1002/jmv.26951
Zhao Y, Patel J, Huang Y, et al. Cardiac markers of multisystem inflammatory syndrome in children (MIS-C) in COVID-19 patients: a meta-analysis. Am J Emerg Med 2021;49:62–70. DOI: 10.1016/j.ajem.2021.05.044
Belhadjer Z, Meot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-COV-2 pandemic. Circulation 2020;142(5):429–436. DOI: 10.1161/CIRCULATIONAHA.120.048360
Niaz T, Hope K, Fremed M, et al. Role of a pediatric cardiologist in the COVID-19 pandemic. Pediatr Cardiol 2020;42(1):19–35. DOI: 10.1007/s00246-020-02476-y